Arcturus Research Development from 2010 to 2026
| ARCT Stock | USD 7.47 0.10 1.32% |
Research Development | First Reported 2012-06-30 | Previous Quarter 29.6 M | Current Value 23.3 M | Quarterly Volatility 18.9 M |
Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 M, Interest Expense of 0.0 or Selling General Administrative of 63.8 M, as well as many indicators such as Price To Sales Ratio of 2.83, Dividend Yield of 0.001 or PTB Ratio of 1.8. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.
Arcturus | Research Development | Build AI portfolio with Arcturus Stock |
The evolution of Research Development for Arcturus Therapeutics Holdings provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Arcturus Therapeutics compares to historical norms and industry peers.
Latest Arcturus Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of Arcturus Therapeutics Holdings over the last few years. It is Arcturus Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcturus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Arcturus Research Development Regression Statistics
| Arithmetic Mean | 80,103,016 | |
| Geometric Mean | 27,633,036 | |
| Coefficient Of Variation | 112.56 | |
| Mean Deviation | 80,972,021 | |
| Median | 25,105,000 | |
| Standard Deviation | 90,162,998 | |
| Sample Variance | 8129.4T | |
| Range | 234.8M | |
| R-Value | 0.90 | |
| Mean Square Error | 1578.8T | |
| R-Squared | 0.82 | |
| Slope | 16,147,938 | |
| Total Sum of Squares | 130069.9T |
Arcturus Research Development History
About Arcturus Therapeutics Financial Statements
Arcturus Therapeutics shareholders use historical fundamental indicators, such as Research Development, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcturus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcturus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Research Development | 224.4 M | 235.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.